Navigation Links
Concert Medical Launches 'Conductor™' Family of Interventional Coronary Guidewires
Date:7/14/2010

NORWELL, Mass., July 14 /PRNewswire/ -- Concert Medical, LLC today announced the launch of the "Conductor™" family of Interventional Coronary Guidewires to the U.S. market. These guidewires are designed to address an extensive range of coronary disease cases at a superior value. The FDA granted Concert Medical clearance for the use and sale in the U.S. of the Conductor product line in September 2009. Concert Medical is located in Norwell, Mass. and manufactures all of its interventional products in the United States.

Concert Medical is an integrated medical device manufacturer, directly controlling all design and critical manufacturing processes for its interventional products. This business integration ensures both product quality and greater value. Concert's Conductor guidewires offer enhanced trackability and crossability, with an increased reliable strength and superior torque response. Performance-enhancing design features include a proprietary hydrophilic coating to improve tactile feel and shaft markers at 90cm and 100cm for precise insertion measurement.

Howard Donnelly, President of Concert Medical, said the Conductor is the firm's second guidewire product released in 2010.  "Earlier this year we launched a private-labeled neurological guidewire, co-developed with a leading medical device company," noted Donnelly. "The Conductor, which we spent two years developing, is an outstanding addition to our interventional guidewire business."

Concert Medical, formerly The MicroSpring Company, was founded in 1982 as an exclusively contract manufacturer and was acquired by Donnelly and his partners in 2005. Since the acquisition, Donnelly has moved Concert from a contract manufacturer to a private label and proprietary medical device product developer.  "Whether it's for our own product line or private labeled for a customer, we add a lot of value to the design and manufacturing of medical products," noted Donnelly. "With close to 30 years of experience in the fields of Interventional Cardiology and Interventional Neurology, we have the knowledge, expertise, and resources to bring innovative products and updates to the marketplace."

Interventional Cardiologists interested in the Conductor can contact Emily O'Connor, Product Manager, at 781-871-7882, x151 or at emily.oconnor@concertmedical.com. For additional information on Concert Medical and its products, visit www.concertmedical.com.


'/>"/>
SOURCE Concert Medical, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
2. CONCERTA(R) Patent Appeal Denied
3. CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD
4. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
5. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
6. Varian Medical Systems to Showcase Fast, Precise Brachytherapy Planning System at Annual Meeting of American Association of Physicists in Medicine
7. Parkview Medical Center Selects MobileMD for Health Information Exchange Service
8. Medical Alarm Concepts™ Announces Roll-Out of the MediPendant™ at Albertsons
9. Dehaier Medical Systems Acquires Emergency Ventilator Series to Extend Product Line
10. New White Paper Helps Medical Device Manufacturers Apply New FDA Regs to Combination Products
11. Crux Biomedical Named One of Top 50 Companies to Watch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
Breaking Medicine News(10 mins):